Cargando…
The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy
Antibodies against checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) and its ligand anti-programmed death ligand 1 (PD-L1) have shown clinical efficacy in the treatment of multiple cancers. However, there are only a few studies on biomarkers for these targeted immunotherapies...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072287/ https://www.ncbi.nlm.nih.gov/pubmed/33912192 http://dx.doi.org/10.3389/fimmu.2021.665147 |
_version_ | 1783683887294054400 |
---|---|
author | Wu, Liangliang Xie, Shengzhi Wang, Lingxiong Li, Jinfeng Han, Lu Qin, Boyu Zhang, Guoqing Wu, Qiyan Gao, Wenjuan Zhang, Lijun Wei, Huafeng Liu, Tianyi Jiao, Shunchang |
author_facet | Wu, Liangliang Xie, Shengzhi Wang, Lingxiong Li, Jinfeng Han, Lu Qin, Boyu Zhang, Guoqing Wu, Qiyan Gao, Wenjuan Zhang, Lijun Wei, Huafeng Liu, Tianyi Jiao, Shunchang |
author_sort | Wu, Liangliang |
collection | PubMed |
description | Antibodies against checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) and its ligand anti-programmed death ligand 1 (PD-L1) have shown clinical efficacy in the treatment of multiple cancers. However, there are only a few studies on biomarkers for these targeted immunotherapies, especially in peripheral blood. We first studied the role of interferon-induced protein-10 (IP10) combined with interleukin-8 (IL-8) in peripheral blood as a biomarker of immune-combined chemotherapy for lung cancer and multiple cancers. We used the high-throughput cytokine detection platform and performed bioinformatics analysis of blood samples from 67 patients with lung cancer and 24 with multiple cancers. We selected the ratio of IP-10 to IL-8 (S2/S0, ratio of changes at 10–12 weeks after treatment to baseline) to predict the response to immunotherapy combined with chemotherapy and evaluate the survival of lung cancer patients and mixed cancer patients. In patients treated with the combination therapy, the specificity and sensitivity of IL-8 and IP10 together as predictors were improved compared with those of IL-8 and IP10 alone. Our conclusion was verified in not only lung cancer but also multiple cancer research cohorts. We then further validated the predictive effect of biomarkers in different histologic types of NSCLC and chemotherapy combined with different PD-1 drug groups. Subsequent validation should be conducted with a larger number of patients. The proposed marker IP10 (S2/S0)/IL-8 (S2/S0), as a predictive immunotherapy biomarker, has broad prospects for future clinical applications in treating patients with multiple intractable neoplasms. |
format | Online Article Text |
id | pubmed-8072287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80722872021-04-27 The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy Wu, Liangliang Xie, Shengzhi Wang, Lingxiong Li, Jinfeng Han, Lu Qin, Boyu Zhang, Guoqing Wu, Qiyan Gao, Wenjuan Zhang, Lijun Wei, Huafeng Liu, Tianyi Jiao, Shunchang Front Immunol Immunology Antibodies against checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) and its ligand anti-programmed death ligand 1 (PD-L1) have shown clinical efficacy in the treatment of multiple cancers. However, there are only a few studies on biomarkers for these targeted immunotherapies, especially in peripheral blood. We first studied the role of interferon-induced protein-10 (IP10) combined with interleukin-8 (IL-8) in peripheral blood as a biomarker of immune-combined chemotherapy for lung cancer and multiple cancers. We used the high-throughput cytokine detection platform and performed bioinformatics analysis of blood samples from 67 patients with lung cancer and 24 with multiple cancers. We selected the ratio of IP-10 to IL-8 (S2/S0, ratio of changes at 10–12 weeks after treatment to baseline) to predict the response to immunotherapy combined with chemotherapy and evaluate the survival of lung cancer patients and mixed cancer patients. In patients treated with the combination therapy, the specificity and sensitivity of IL-8 and IP10 together as predictors were improved compared with those of IL-8 and IP10 alone. Our conclusion was verified in not only lung cancer but also multiple cancer research cohorts. We then further validated the predictive effect of biomarkers in different histologic types of NSCLC and chemotherapy combined with different PD-1 drug groups. Subsequent validation should be conducted with a larger number of patients. The proposed marker IP10 (S2/S0)/IL-8 (S2/S0), as a predictive immunotherapy biomarker, has broad prospects for future clinical applications in treating patients with multiple intractable neoplasms. Frontiers Media S.A. 2021-04-12 /pmc/articles/PMC8072287/ /pubmed/33912192 http://dx.doi.org/10.3389/fimmu.2021.665147 Text en Copyright © 2021 Wu, Xie, Wang, Li, Han, Qin, Zhang, Wu, Gao, Zhang, Wei, Liu and Jiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wu, Liangliang Xie, Shengzhi Wang, Lingxiong Li, Jinfeng Han, Lu Qin, Boyu Zhang, Guoqing Wu, Qiyan Gao, Wenjuan Zhang, Lijun Wei, Huafeng Liu, Tianyi Jiao, Shunchang The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy |
title | The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy |
title_full | The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy |
title_fullStr | The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy |
title_full_unstemmed | The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy |
title_short | The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy |
title_sort | ratio of ip10 to il-8 in plasma reflects and predicts the response of patients with lung cancer to anti-pd-1 immunotherapy combined with chemotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072287/ https://www.ncbi.nlm.nih.gov/pubmed/33912192 http://dx.doi.org/10.3389/fimmu.2021.665147 |
work_keys_str_mv | AT wuliangliang theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT xieshengzhi theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT wanglingxiong theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT lijinfeng theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT hanlu theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT qinboyu theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT zhangguoqing theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT wuqiyan theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT gaowenjuan theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT zhanglijun theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT weihuafeng theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT liutianyi theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT jiaoshunchang theratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT wuliangliang ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT xieshengzhi ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT wanglingxiong ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT lijinfeng ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT hanlu ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT qinboyu ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT zhangguoqing ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT wuqiyan ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT gaowenjuan ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT zhanglijun ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT weihuafeng ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT liutianyi ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy AT jiaoshunchang ratioofip10toil8inplasmareflectsandpredictstheresponseofpatientswithlungcancertoantipd1immunotherapycombinedwithchemotherapy |